David Taber to Transplant Recipients
This is a "connection" page, showing publications David Taber has written about Transplant Recipients.
Connection Strength
6.969
-
Clinical Outcomes of Older Kidney Transplant Recipients. Am J Med Sci. 2021 08; 362(2):130-134.
Score: 0.658
-
Long-term Assessment of NSAID Prescriptions and Potential Nephrotoxicity Risk in Adult Kidney Transplant Recipients. Transplantation. 2019 12; 103(12):2675-2681.
Score: 0.604
-
Using informatics and mobile health to improve medication safety monitoring in kidney transplant recipients. Am J Health Syst Pharm. 2019 Jul 18; 76(15):1143-1149.
Score: 0.588
-
The impact of time-varying clinical surrogates on disparities in African-American kidney transplant recipients - a retrospective longitudinal cohort study. Transpl Int. 2019 01; 32(1):84-94.
Score: 0.555
-
Characterization of Potentially Unsafe Ambulatory Antibiotic Use and Associated Outcomes in an Adult Kidney Transplant Population. Ann Pharmacother. 2018 10; 52(10):974-982.
Score: 0.543
-
Transplant Center Variability in Disparities for African-American Kidney Transplant Recipients. Ann Transplant. 2018 Feb 16; 23:119-128.
Score: 0.533
-
Improvement in immunosuppression therapy monitoring in organ transplant recipients. Am J Health Syst Pharm. 2017 Sep 01; 74(17 Supplement 3):S67-S74.
Score: 0.517
-
Development of a Predictive Model for Drug-Related Problems in Kidney Transplant Recipients. Pharmacotherapy. 2017 02; 37(2):159-169.
Score: 0.496
-
Outcome disparities between African Americans and Caucasians in contemporary kidney transplant recipients. Am J Surg. 2017 Apr; 213(4):666-672.
Score: 0.489
-
Twenty years of evolving trends in racial disparities for adult kidney transplant recipients. Kidney Int. 2016 10; 90(4):878-87.
Score: 0.481
-
Kidney transplant recipients' attitudes about using mobile health technology for managing and monitoring medication therapy. J Am Pharm Assoc (2003). 2016 Jul-Aug; 56(4):450-454.e1.
Score: 0.476
-
Impact of Pharmacist Involvement in Early Identification and Enrollment in Patient Assistance Programs on CMV Outcomes in Transplantation. J Pharm Pract. 2016 Apr; 29(2):97-102.
Score: 0.418
-
Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients. Ther Drug Monit. 2021 06 01; 43(3):401-407.
Score: 0.167
-
Quantifying the Race Stratified Impact of Socioeconomics on Graft Outcomes in Kidney Transplant Recipients. Transplantation. 2016 07; 100(7):1550-7.
Score: 0.119
-
Optimizing finite resources: Pharmacist chart reviews in an outpatient kidney transplant clinic. J Am Pharm Assoc (2003). 2015 Nov-Dec; 55(6):613-620.
Score: 0.114
-
Prediction of medication non-adherence and associated outcomes in pediatric kidney transplant recipients. Pediatr Transplant. 2015 Aug; 19(5):555-62.
Score: 0.110
-
Patterns of emergency department utilization between transplant and non-transplant centers and impact on clinical outcomes in kidney recipients. Clin Transplant. 2020 09; 34(9):e13983.
Score: 0.039
-
Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200?days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study. Transpl Infect Dis. 2017 Dec; 19(6).
Score: 0.033
-
A randomized, prospective comparison of transition to sirolimus-based CNI-minimization or withdrawal in African American kidney transplant recipients. Clin Transplant. 2016 05; 30(5):528-33.
Score: 0.029